
Kiays Khalil
International Multimedia Journalist at The TRADE
International Journalist & Man of all the Medias @globalcustodian @theTRADEnews all tweets are my own opinions
Articles
-
Dec 6, 2023 |
medicaldevice-network.com | Kiays Khalil
The year has had ups and downs from artificial intelligence regulation to industry wide layoffs there has been a lot to cover. The Medical Device Network has put together a short video to recap the biggest events of the year to help you process the news going into 2024. How well do you know your competitors? Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge. Not ready to buy yet?
-
Dec 5, 2023 |
medicaldevice-network.com | Kiays Khalil
Paris-based artificial organ developer CARMAT has announced it will open a new production facility in Bois-d’Arcy, France. This will be the second facility opened by the company which will be in the same vicinity as their first operations site. The new facility has been reviewed by the notified body DEKRA who approved it to produce the Aeson total artificial heart, a therapeutic alternative for people with end-stage biventricular heart failure also known as congestive heart failure.
-
Dec 4, 2023 |
medicaldevice-network.com | Kiays Khalil
GE Healthcare has entered into a distribution agreement with mobile-first clinical surveillance technology provider, AirStrip to expand AirStrip Cardiology and Patient Monitoring solutions in the US. The mobile application from AirStrip enables clinicians to view clinical data on the web and on mobile devices. It connects with cardiac rhythm strips and 12-lead ECGs, allowing clinicians to monitor numerous patients at the same time and can receive STEMI notifications.
-
Dec 4, 2023 |
medicaldevice-network.com | Kiays Khalil
Pharmaceutical company, Qnovia has shared positive results from initial clinical trials of its prescription inhaled smoking cessation therapy. The drug delivery platform, QN-01, is under evaluation in the US through the US Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research (CDER) while the Medicines and Healthcare Products Regulatory Agency (MHRA) reviews it in the UK.
-
Dec 3, 2023 |
clinicaltrialsarena.com | Kiays Khalil
The year 2023 has seen the first CRISPR therapy indicate it could be a one-time success for patients with sickle cell disease as well as more movement in the field of Alzheimer’s disease. In this video, the Clinical Trials Arena evaluates some significant trials of the year as well as some important regulatory changes in both Europe and the US. More Relevant
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 186
- Tweets
- 621
- DMs Open
- Yes

RT @globalcustodian: Coming into effect in September, #SEC #Rule2a5 sets out guidance in assessing fair value of fund investments @SPGlobal…

RT @globalcustodian: Don't miss our latest #SmarterSecurities podcast in association with SWIFT discussing #settlement time and the use of…

RT @theTRADEnews: How can the trading desk protect itself from growing risks due to previous financial misconduct? Myles McGuinness CEO at…